Summit Therapeutics stock drops 3.94% as FDA accepts BLA for Ivonescimab in NSCLC
Summit Therapeutics said the U.S. FDA has accepted its Biologics License Application seeking approval for ivonescimab in combination with chemotherapy in the treatment of patients with EGFRm NSCLC ...